Ongoing Clinical Trials for Epithelioid Sarcoma
Currently, there is 1 ongoing clinical trial for epithelioid sarcoma. This trial focuses on evaluating the long-term safety of tazemetostat, a targeted medication that works by blocking specific enzymes in cancer cells. The study is being conducted in France and Poland and is open to patients who have previously participated in other tazemetostat trials and have shown benefit from the treatment.
Clinical trial locations
- France
- Poland
Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials
This trial evaluates the long-term safety of tazemetostat, a targeted cancer medication taken as a tablet by mouth. The study is designed for patients who have already been treated with tazemetostat in previous clinical trials and have experienced clinical benefit from the treatment.
Main inclusion criteria:
- You must be currently benefiting from tazemetostat treatment
- You must be currently receiving tazemetostat either alone or in combination with other medications as part of a clinical trial
- You must have a life expectancy of more than 3 months
- Your blood tests must show adequate blood cell counts, bone marrow function, kidney function, and liver function
- Women who can become pregnant must have a negative pregnancy test and agree to use both a highly effective birth control method and a barrier method during treatment and for 6 months after the last dose
- Male participants must either have had a vasectomy and use condoms, or their female partner must use effective contraception, during treatment and for 3 months after stopping treatment
Main exclusion criteria:
- You cannot participate if you are not currently receiving tazemetostat treatment in a previous clinical study
- You cannot join if you experienced severe side effects during previous treatment with tazemetostat
- You are not eligible if you have developed progressive disease while on tazemetostat treatment
- You cannot participate if you are unable to comply with the long-term safety monitoring requirements
- You are excluded if you are participating in other clinical trials simultaneously
- You cannot join if you have developed any medical condition that makes continued treatment unsafe
Focus and goal of the trial:
The primary goal of this study is to monitor the long-term safety of tazemetostat in patients who continue to receive the medication. Researchers will carefully track any side effects that may occur and evaluate how well patients tolerate the medication over an extended period. The study will monitor various health measures, including blood cell counts, kidney function, and liver function. Additionally, the research team will track how long patients survive while receiving the treatment. This is an open-label study, meaning all participants will receive the active medication without the use of a placebo. The study is planned to continue until September 2025.
Investigational drug:
Tazemetostat is a medication that belongs to a class of drugs called EZH2 inhibitors. It works by blocking the EZH2 protein, which plays an important role in controlling gene expression and cancer cell growth. The medication is given as film-coated tablets taken by mouth, following the same dosage pattern as in your previous treatment program. Tazemetostat represents an innovative approach in targeted cancer therapy and is being studied for its effectiveness in various types of cancers, including certain solid tumors and lymphomas with specific genetic characteristics.
Summary
Currently, there is one clinical trial available for patients with epithelioid sarcoma. This trial is being conducted in two European countries: France and Poland. The study specifically targets patients who have already received tazemetostat treatment in previous clinical trials and have shown clinical benefit from this medication.
The trial focuses exclusively on evaluating the long-term safety profile of tazemetostat, an EZH2 inhibitor that represents a targeted approach to cancer treatment. This study provides an opportunity for patients who are responding well to tazemetostat to continue their treatment while contributing to important research about the medication’s safety over extended periods.
It is important to note that this trial has specific eligibility requirements, particularly regarding previous participation in tazemetostat studies and demonstrated clinical benefit from the medication. Patients interested in this trial should discuss their eligibility with their healthcare provider, especially if they have previously received tazemetostat treatment.